# Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

> **NCT00874796** · PHASE2 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 307 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** GS-9450
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00874796
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-05
- **Primary completion:** 2010-04
- **Final completion:** 2010-07
- **Target enrollment:** 307 (ACTUAL)
- **Why stopped:** Reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.
- **Last updated:** 2014-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00874796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00874796, "Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00874796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*